Acne 

Actinic Keratosis 

Aesthetics

Alopecia

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

Buy-and-Bill

COVID-19

Case-Based Roundtable

Chronic Hand Eczema

Chronic Spontaneous Urticaria 

Drug Watch

Eczema

General Dermatology 

Hidradenitis Suppurativa

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Prurigo Nodularis

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Vitiligo

Wound Care

News

Media

Around the Practice

Between The Lines

Case-Based Peer Perspective

Clinical Case Collective

DermView

Expert Perspectives

Fellows Face Off

Frontline Forum

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Conferences

Conference Coverage

Conference Listing

Events

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Interactive Tools

Job Board

Partner Perspectives

Perspectives in Dermatology

Polls

Spot Test

Editorial Advisory Board

Partners

Subscribe

and joined the MJH Life Sciences team in February 2023. She attended Kent State University and earned a Bachelor of Science degree in journalism with minors in public relations and creative writing. She enjoys making and listening to music, reading, and spending time with her cats, Astrid and Marceline.

Articles

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Daily Derm Times: July 10, 2025

Maddi Hebebrand is an associate editor of 

and joined the MJH Life Sciences team in May 2024. She attended Baldwin Wallace University, studying Media Production and Film, and received her Masters in Digital Media from Ohio University. When she's not writing, Maddi loves to read, attend concerts and spend time with her family. 

A pilot study evaluates tildrakizumab's safety and potential in treating stable non-segmental vitiligo, highlighting the need for further research on IL-23 inhibitors.

IL-23 Inhibitor Fails to Improve VASI in Pilot Trial

Zelsuvmi is the first FDA-approved at-home treatment for molluscum contagiosum, now available for patients aged ≥1 via retail and mail-order pharmacies.

Zelsuvmi, First At-Home Prescription Gel for Molluscum Contagiosum, Launches in US

Christopher Bunick, MD, PhD, is an associate professor of dermatology and physician-scientist at the Yale School of Medicine in New Haven, Connecticut, and 

Christopher Bunick, MD, PhD, highlights how dupilumab transforms atopic dermatitis treatment in children, improving health outcomes and quality of life beyond skin symptoms.

Systemic Therapy for Pediatric Atopic Dermatitis: A Growing Case for Early Intervention

Dermatology Times connects dermatology professionals with key skin disorder coverage, therapeutic strategies, clinical trial updates, and expert insights.

About

Advertise

Contact Us

Do Not Sell My Information

Terms and Conditions

Privacy Policy

Dermatology Times - Dermatology News and Clinical Insights

Facebook

Linkedin

Topics

Acne

Pigmentary Disorders

Practice Management

Psoriasis

Psoriatic Arthritis

Rosacea

Conference

1rem

Conference Archive

Perspectives: The Evolution of Aesthetics

Victor Ross, MD, board-certified dermatologist and dermatologic surgeon in San Diego, California, spoke about different technologies available for microneedling and energy-based devices. 

Deep Dive into Microneedling with Energy-Based Devices

Opening the symposium in a circle of sparks and salsa dancing, Shino Bay Aguilera, DO, talks the importance of diversity and wellness in aesthetics. 

 Shino Bay Aguilera, DO, Opens ABM Perspectives with a Bang